Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Watanabe

Showing results (751-760 of 817) with videos related to

Pageof 82
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 23, 2021
Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort studyDaichi Fujimoto, Satoru Miura, Kenichi Yoshimura, et al.
Inflammation and Regeneration|November 29, 2022
Collagen type I-mediated mechanotransduction controls epithelial cell fate conversion during intestinal inflammationSakurako Kobayashi, Nobuhiko Ogasawara, Satoshi Watanabe, et al.
Annals of Surgical Oncology|March 4, 2018
Clinical and Genetic Implications of Mutation Burden in Squamous Cell Carcinoma of the LungTatsuro Okamoto, Kazuki Takada, Seijiro Sato, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2019
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in JapanSatoshi Watanabe, Hiroshige Yoshioka, Hiroshi Sakai, et al.
DNA Research : an International Journal for Rapid Publication of Reports on Genes and Genomes|January 15, 2008
An integrated high-density linkage map of soybean with RFLP, SSR, STS, and AFLP markers using A single F2 populationZhengjun Xia, Yasutaka Tsubokura, Masako Hoshi, et al.
European Journal of Cancer (Oxford, England : 1990)|September 16, 2025
A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B studyHiromi Nagashima, Tatsuro Fukuhara, Yu Utsumi, et al.
Scientific Reports|January 13, 2021
Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicityMasashi Arita, Satoshi Watanabe, Nobumasa Aoki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2020
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in <i>EGFR</i>-Mutated Non-Small Cell Lung CancerNaoko Okura, Naoya Nishioka, Tadaaki Yamada, et al.
Journal of Cachexia, Sarcopenia and Muscle|October 1, 2024
Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050AKeita Miura, Takehito Shukuya, Naoki Furuya, et al.
Oncogene|July 2, 2026
Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancerYifeng Liu, Shigeki Nanjo, Yuya Murase, et al.
Pageof 82

Showing results (751-760 of 817) with videos related to

Sort By:
Pageof 82
European Journal of Cancer (Oxford, England : 1990)|April 23, 2021
Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort studyDaichi Fujimoto, Satoru Miura, Kenichi Yoshimura, et al.
Inflammation and Regeneration|November 29, 2022
Collagen type I-mediated mechanotransduction controls epithelial cell fate conversion during intestinal inflammationSakurako Kobayashi, Nobuhiko Ogasawara, Satoshi Watanabe, et al.
Annals of Surgical Oncology|March 4, 2018
Clinical and Genetic Implications of Mutation Burden in Squamous Cell Carcinoma of the LungTatsuro Okamoto, Kazuki Takada, Seijiro Sato, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2019
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in JapanSatoshi Watanabe, Hiroshige Yoshioka, Hiroshi Sakai, et al.
DNA Research : an International Journal for Rapid Publication of Reports on Genes and Genomes|January 15, 2008
An integrated high-density linkage map of soybean with RFLP, SSR, STS, and AFLP markers using A single F2 populationZhengjun Xia, Yasutaka Tsubokura, Masako Hoshi, et al.
European Journal of Cancer (Oxford, England : 1990)|September 16, 2025
A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B studyHiromi Nagashima, Tatsuro Fukuhara, Yu Utsumi, et al.
Scientific Reports|January 13, 2021
Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicityMasashi Arita, Satoshi Watanabe, Nobumasa Aoki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2020
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in <i>EGFR</i>-Mutated Non-Small Cell Lung CancerNaoko Okura, Naoya Nishioka, Tadaaki Yamada, et al.
Journal of Cachexia, Sarcopenia and Muscle|October 1, 2024
Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050AKeita Miura, Takehito Shukuya, Naoki Furuya, et al.
Oncogene|July 2, 2026
Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancerYifeng Liu, Shigeki Nanjo, Yuya Murase, et al.
Pageof 82